ScoreComparison
Why is Zomedica Corp. ?
1
With a growth in Net Sales of 36.59%, the company declared Outstanding results in Jun 26
- The company has declared positive results for the last 2 consecutive quarters
- OPERATING CASH FLOW(Y) Highest at USD -13.15 MM
- ROCE(HY) Highest at -16.29%
- OPERATING PROFIT(Q) Highest at USD -2.24 MM
2
MFs have decreased holdings this quarter and now hold 1.08% of the company
3
Market Beating Performance
- The stock has generated a return of 120.21% in the last 1 year, much higher than market (S&P 500) returns of 15.36%
Real-Time Research ReportHow much should you buy?
- Overall Portfolio exposure to Zomedica Corp. should be less than 10%
- Overall Portfolio exposure to Pharmaceuticals & Biotechnology should be less than 30%
(If sector exposure > 30%, please use optimiser tool to see which are the best stocks to hold in Pharmaceuticals & Biotechnology)
When to exit? - We will constantly monitor the company and suggest at the appropriate time to exit from the stock
Is Zomedica Corp. for you?
High Risk, Low Return
Absolute
Risk Adjusted
Volatility
Zomedica Corp.
120.21%
-0.90
72.94%
S&P 500
15.76%
1.17
13.09%
Quality
Management Risk
Growth
Capital StructureQuality key factors
Factor
Value
Sales Growth (5y)
101.27%
EBIT Growth (5y)
-21.49%
EBIT to Interest (avg)
-27.69
Debt to EBITDA (avg)
Negative Net Debt
Net Debt to Equity (avg)
-0.48
Sales to Capital Employed (avg)
0.17
Tax Ratio
0.44%
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
10.10%
ROCE (avg)
0
ROE (avg)
0
ValuationValuation Key Factors 
Factor
Value
P/E Ratio
NA (Loss Making)
Industry P/E
Price to Book Value
1.08
EV to EBIT
-2.51
EV to EBITDA
-3.49
EV to Capital Employed
1.14
EV to Sales
2.24
PEG Ratio
NA
Dividend Yield
NA
ROCE (Latest)
-45.37%
ROE (Latest)
-22.55%
TechnicalsTechnical key factors
Indicator
Weekly
Monthly
MACD
Mildly Bearish
Mildly Bullish
RSI
No Signal
Bearish
Bollinger Bands
Mildly Bearish
Mildly Bullish
Moving Averages
Mildly Bullish (Daily)
KST
Mildly Bearish
Bullish
Dow Theory
No Trend
No Trend
OBV
No Trend
Mildly Bearish
Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish Turned 
Financial Trend24What is working for the Company
OPERATING CASH FLOW(Y)
Highest at USD -13.15 MM
ROCE(HY)
Highest at -16.29%
OPERATING PROFIT(Q)
Highest at USD -2.24 MM
PRE-TAX PROFIT(Q)
Highest at USD -3.74 MM
NET SALES(Q)
At USD 9.51 MM has Grown at 36.59%
OPERATING PROFIT MARGIN(Q)
Highest at -23.55 %
NET PROFIT(Q)
Highest at USD -3.77 MM
EPS(Q)
Highest at USD -0
-3What is not working for the Company
RAW MATERIAL COST(Y)
Grown by 5.29% (YoY
CASH AND EQV(HY)
Lowest at USD 91.64 MM
DEBTORS TURNOVER RATIO(HY)
Lowest at 8.25 times
Here's what is working for Zomedica Corp.
Operating Cash Flow
Highest at USD -13.15 MM and Grown
In each year in the last three yearsMOJO Watch
The company has generated higher cash revenues from business operations
Operating Cash Flows (USD MM)
Operating Profit
Highest at USD -2.24 MM and Grown
In each period in the last five periodsMOJO Watch
Near term Operating Profit trend is quite positive
Operating Profit (USD MM)
Pre-Tax Profit
Highest at USD -3.74 MM and Grown
In each period in the last five periodsMOJO Watch
Near term Pre-Tax Profit trend is very positive
Pre-Tax Profit (USD MM)
Net Sales
At USD 9.51 MM has Grown at 36.59%
Year on Year (YoY)MOJO Watch
Near term sales trend is positive
Net Sales (USD MM)
Operating Profit Margin
Highest at -23.55 %
in the last five periodsMOJO Watch
Company's profit margin has improved
Operating Profit to Sales
Net Profit
Highest at USD -3.77 MM
in the last five periodsMOJO Watch
Near term Net Profit trend is positive
Net Profit (USD MM)
EPS
Highest at USD -0
in the last five periodsMOJO Watch
Increasing profitability; company has created higher earnings for shareholders
EPS (USD)
Here's what is not working for Zomedica Corp.
Cash and Eqv
Lowest at USD 91.64 MM
in the last six Semi-Annual periodsMOJO Watch
Short Term liquidity is deteriorating
Cash and Cash Equivalents
Debtors Turnover Ratio
Lowest at 8.25 times
in the last five Semi-Annual periodsMOJO Watch
Company's pace of selling Debtors has slowed
Debtors Turnover Ratio
Raw Material Cost
Grown by 5.29% (YoY)
MOJO Watch
The company's ability to pass on the cost of raw materials to customers has deteriorated; this may lead to a fall in profit margin
Raw Material Cost as a percentage of Sales
Footer loading
